Concourse Financial Group Securities, Inc. Biotechnology

Concourse Financial Group Securities, Inc.

$1.67 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
NVO Novo Nordisk A S	$205B	$3.26 Million 0.2% of portfolio	37,910	Q4 2024 Reduced 18.62%
VRTX Vertex Pharmaceuticals Inc	$123B	$2.69 Million 0.16% of portfolio	6,677	Q4 2024 Added 36.52%
VKTX Viking Therapeutics, Inc.	$2.21B	$98,000 0.01% of portfolio	2,450	Q4 2024 Added 250.0%
EXEL Exelixis, Inc.	$12.5B	$92,000 0.01% of portfolio	2,787	Q4 2024 Reduced 17.08%
REGN Regeneron Pharmaceuticals, Inc.	$74.9B	$84,000 0.01% of portfolio	119	Q4 2024 Added 116.36%
INCY Incyte Corp	$16.3B	$83,000 0.0% of portfolio	1,212	Q4 2024 Reduced 19.36%
XENE Xenon Pharmaceuticals Inc.	$2.3B	$78,000 0.0% of portfolio	2,000	Q4 2019 Added 100.0%
NTLA Intellia Therapeutics, Inc.	$767M	$60,000 0.0% of portfolio	5,216	Q4 2024 Added 71.18%
CPRX Catalyst Pharmaceuticals, Inc.	$2.35B	$53,000 0.0% of portfolio	2,570	Q4 2024 New
JAZZ Jazz Pharmaceuticals PLC	$9B	$45,000 0.0% of portfolio	372	Q4 2024 Added 6.9%
HALO Halozyme Therapeutics, Inc.	$8.24B	$42,000 0.0% of portfolio	897	Q4 2024 Reduced 10.12%
SRPT Sarepta Therapeutics, Inc.	$9.35B	$26,000 0.0% of portfolio	221	Q4 2024 Reduced 5.15%
MRNA Moderna, Inc.	$12.1B	$24,000 0.0% of portfolio	601	Q4 2024 Reduced 7.54%
TECH Bio Techne Corp	$2.42B	$11,000 0.0% of portfolio	156	Q4 2024 Reduced 21.61%
GMAB Genmab A/S	$14.9B	$8,000 0.0% of portfolio	390	Q4 2024 Added 0.52%
CRSP Crispr Therapeutics Ag	$3.43B	$7,000 0.0% of portfolio	200	Q3 2024 Reduced 25.65%
LGND Ligand Pharmaceuticals Inc	$2.06B	$7,000 0.0% of portfolio	72	Q2 2023 Reduced 17.24%
HUMA Humacyte, Inc.	$350M	$5,000 0.0% of portfolio	1,000	Q2 2024 New
AMRN Amarin Corp Plcuk	$218M	$3,000 0.0% of portfolio	8,000	Q4 2022 New
ORMP Oramed Pharmaceuticals Inc.	$81.1M	$2,000 0.0% of portfolio	1,000	Q3 2021 New
ALNY Alnylam Pharmaceuticals, Inc.	$30.4B	$1,000 0.0% of portfolio	5	Q4 2024 Added 66.67%
HRTX Heron Therapeutics, Inc.	$293M	$1,000 0.0% of portfolio	1,280	Q3 2024 Reduced 18.99%
RVNC Revance Therapeutics, Inc.	$212M	$1,000 0.0% of portfolio	570	Q1 2024 New
RPRX Royalty Pharma PLC	$14.7B	$1,000 0.0% of portfolio	47	Q4 2024 Reduced 47.19%
ONCY Oncolytics Biotech Inc	$38.2M	$0 0.0% of portfolio	0	Q4 2024 New
OPNT Opiant Pharmaceuticals, Inc.	$0	$0 0.0% of portfolio	0	Q4 2024 New
OGEN Oragenics Inc	$33.8M	$0 0.0% of portfolio	0	Q4 2024 New
ORTX Orchard Therapeutics PLC	$0	$0 0.0% of portfolio	0	Q4 2024 New
ONVO Organovo Holdings, Inc.	$5.66M	$0 0.0% of portfolio	0	Q4 2024 New
ORIC Oric Pharmaceuticals, Inc.	$318M	$0 0.0% of portfolio	0	Q4 2024 New
OVID Ovid Therapeutics Inc.	$37.3M	$0 0.0% of portfolio	0	Q4 2024 New
OYST Oyster Point Pharma, Inc.	$0	$0 0.0% of portfolio	0	Q4 2024 New
PBLA Panbela Therapeutics, Inc.	$7.69M	$0 0.0% of portfolio	0	Q4 2024 New
KTTAW Pasithea Therapeutics Corp Wt	$0	$0 0.0% of portfolio	0	Q4 2024 New
PASG Passage Bio, Inc.	$28.3M	$0 0.0% of portfolio	0	Q4 2024 New
PDSB Pds Biotechnology Corp	$37.9M	$0 0.0% of portfolio	0	Q4 2024 New
PEPG Pep Gen Inc.	$74.4M	$0 0.0% of portfolio	0	Q4 2024 New
PMCB Pharma Cyte Biotech, Inc.	$36.5M	$0 0.0% of portfolio	0	Q4 2024 New
PHAR Pharming Group N.V.	$566M	$0 0.0% of portfolio	0	Q4 2024 New
PHVS Pharvaris N.V.	$537M	$0 0.0% of portfolio	0	Q4 2024 New
PHAT Phathom Pharmaceuticals, Inc.	$216M	$0 0.0% of portfolio	0	Q4 2024 New
PHIO Phio Pharmaceuticals Corp.	$19.4M	$0 0.0% of portfolio	0	Q4 2024 New
PLRX Pliant Therapeutics, Inc.	$167M	$0 0.0% of portfolio	0	Q4 2024 New
PMVP Pmv Pharmaceuticals, Inc.	$62.5M	$0 0.0% of portfolio	0	Q4 2024 New
PSTX Poseida Therapeutics, Inc.	$815M	$0 0.0% of portfolio	0	Q4 2024 New
PGEN Precigen, Inc.	$360M	$0 0.0% of portfolio	0	Q4 2024 New
PRLD Prelude Therapeutics Inc	$27.6M	$0 0.0% of portfolio	0	Q4 2024 New
PROK Prokidney Corp Ord Shs Cl A(Cy	$75.7M	$0 0.0% of portfolio	0	Q4 2024 New
PRQR Pro Qr Therapeutics N.V.	$166M	$0 0.0% of portfolio	0	Q4 2024 New
PTIX Protagenic Therapeutics, Inc.New	$5.16M	$0 0.0% of portfolio	0	Q4 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.